alvimopan: Clinical Trials

11 trials of alvimopan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 recruiting, 1 terminated. 11 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 311Completed 8, Recruiting 2, Terminated 1

Follow alvimopan: new trials by email Literature Review of alvimopan trials Research Report on alvimopan

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Surgical Techniques During Cystectomy
Stent placement, Alvimopan - Bladder Cancer
Phase 3RecruitingMemorial Sloan Kettering Cancer Center5302024-11-212026-09-22
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Alvimopan, Placebo - Bladder Cancer
Phase 3RecruitingBrigham and Women's Hospital1362018-10-012023-09-28
Alvimopan as Rescue in Post op Ileus
Alvimopan, Control Group - Colorectal Surgery, Ileus
Phase 3TerminatedSharon Stein142015-12-022022-11-18
Accelerating Gastrointestinal Recovery
Alvimopan, Placebo - Ovarian Cancer, Fallopian Tube Cancer
Phase 3CompletedJamie N. Bakkum-Gamez1462013-01-012016-10-24
Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Alvimopan, Placebo - Bowel Dysfunction, Constipation
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)8052005-08-012017-08-30
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Placebo, Alvimopan, Alviompan - Bowel Dysfunction, Constipation
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4852005-08-012015-09-02
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
alvimopan, Placebo - Bowel Dysfunction, Constipation
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)5182005-08-012015-09-02
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
alvimopan - Ileus
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6602004-06-012016-01-11
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Alvimopan - Ileus
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)5102002-01-012015-07-20
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus
Alvimopan - Ileus
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6662001-12-012015-07-20
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Alvimopan - Ileus
Phase 3CompletedCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4512001-03-012017-08-22

Conditions studied

Ileus (5)  ·  Constipation (3)  ·  Intestinal Diseases (3)  ·  Pain (3)  ·  Urinary Bladder Neoplasms (2)  ·  Fallopian Tube Neoplasms (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (7)  ·  Brigham and Women's Hospital (1)  ·  Jamie N. Bakkum-Gamez (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Sharon Stein (1)

Countries

United States (11)  ·  Canada (3)  ·  Australia (2)  ·  Austria (2)  ·  Denmark (2)  ·  Finland (2)  ·  Hungary (2)  ·  Ireland (2)  ·  Netherlands (2)  ·  New Zealand (2)  ·  Poland (2)  ·  Spain (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  United Kingdom (2)

Top investigators

Alvin Goh, MD (1)  ·  Jamie Bakkum-Gamez, MD (1)  ·  Mark A Preston, MD (1)  ·  Sharon Stein, MD (1)

Results publications

PMID 20526599, PMID 15383800, PMID 15906123, PMID 16333556, PMID 19015469, PMID 21292168, PMID 21292169